128 related articles for article (PubMed ID: 19628566)
21. Expression of both estrogen receptor-beta 1 (ER-β1) and its co-regulator steroid receptor RNA activator protein (SRAP) are predictive for benefit from tamoxifen therapy in patients with estrogen receptor-alpha (ER-α)-negative early breast cancer (EBC).
Yan Y; Li X; Blanchard A; Bramwell VH; Pritchard KI; Tu D; Shepherd L; Myal Y; Penner C; Watson PH; Leygue E; Murphy LC
Ann Oncol; 2013 Aug; 24(8):1986-93. PubMed ID: 23579816
[TBL] [Abstract][Full Text] [Related]
22. The role of amplified in breast cancer 1 in breast cancer: A meta-analysis.
Hou J; Liu J; Yuan M; Meng C; Liao J
Medicine (Baltimore); 2020 Nov; 99(46):e23248. PubMed ID: 33181714
[TBL] [Abstract][Full Text] [Related]
23. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women.
Sharma R; Hamilton A; Beith J
Cochrane Database Syst Rev; 2008 Oct; (4):CD004562. PubMed ID: 18843661
[TBL] [Abstract][Full Text] [Related]
24. Quantitative measurement of epidermal growth factor receptor is a negative predictive factor for tamoxifen response in hormone receptor positive premenopausal breast cancer.
Giltnane JM; Rydén L; Cregger M; Bendahl PO; Jirström K; Rimm DL
J Clin Oncol; 2007 Jul; 25(21):3007-14. PubMed ID: 17634479
[TBL] [Abstract][Full Text] [Related]
25. Prognosis and treatment of patients with breast tumors of one centimeter or less and negative axillary lymph nodes.
Fisher B; Dignam J; Tan-Chiu E; Anderson S; Fisher ER; Wittliff JL; Wolmark N
J Natl Cancer Inst; 2001 Jan; 93(2):112-20. PubMed ID: 11208880
[TBL] [Abstract][Full Text] [Related]
26. Adjuvant tamoxifen-induced mammographic breast density reduction as a predictor for recurrence in estrogen receptor-positive premenopausal breast cancer patients.
Ko KL; Shin IS; You JY; Jung SY; Ro J; Lee ES
Breast Cancer Res Treat; 2013 Dec; 142(3):559-67. PubMed ID: 24233999
[TBL] [Abstract][Full Text] [Related]
27. AIB1 is required for the acquisition of epithelial growth factor receptor-mediated tamoxifen resistance in breast cancer cells.
Zhao W; Zhang Q; Kang X; Jin S; Lou C
Biochem Biophys Res Commun; 2009 Mar; 380(3):699-704. PubMed ID: 19285025
[TBL] [Abstract][Full Text] [Related]
28. Tumor-specific expression of vascular endothelial growth factor receptor 2 but not vascular endothelial growth factor or human epidermal growth factor receptor 2 is associated with impaired response to adjuvant tamoxifen in premenopausal breast cancer.
Rydén L; Jirström K; Bendahl PO; Fernö M; Nordenskjöld B; Stål O; Thorstenson S; Jönsson PE; Landberg G
J Clin Oncol; 2005 Jul; 23(21):4695-704. PubMed ID: 16034044
[TBL] [Abstract][Full Text] [Related]
29. Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93.
; Colleoni M; Gelber S; Goldhirsch A; Aebi S; Castiglione-Gertsch M; Price KN; Coates AS; Gelber RD
J Clin Oncol; 2006 Mar; 24(9):1332-41. PubMed ID: 16505417
[TBL] [Abstract][Full Text] [Related]
30. Expression profiling of breast cancer patients treated with tamoxifen: prognostic or predictive significance.
Tabarestani S; Ghaderian SM; Rezvani H; Mirfakhraie R
Med Oncol; 2014 Apr; 31(4):896. PubMed ID: 24563328
[TBL] [Abstract][Full Text] [Related]
31. Optimal systemic therapy for premenopausal women with hormone receptor-positive breast cancer.
Jankowitz RC; McGuire KP; Davidson NE
Breast; 2013 Aug; 22 Suppl 2():S165-70. PubMed ID: 24074781
[TBL] [Abstract][Full Text] [Related]
32. Lack of G protein-coupled estrogen receptor (GPER) in the plasma membrane is associated with excellent long-term prognosis in breast cancer.
Sjöström M; Hartman L; Grabau D; Fornander T; Malmström P; Nordenskjöld B; Sgroi DC; Skoog L; Stål O; Leeb-Lundberg LM; Fernö M
Breast Cancer Res Treat; 2014 May; 145(1):61-71. PubMed ID: 24715381
[TBL] [Abstract][Full Text] [Related]
33. Coassociation of estrogen receptor and p160 proteins predicts resistance to endocrine treatment; SRC-1 is an independent predictor of breast cancer recurrence.
Redmond AM; Bane FT; Stafford AT; McIlroy M; Dillon MF; Crotty TB; Hill AD; Young LS
Clin Cancer Res; 2009 Mar; 15(6):2098-106. PubMed ID: 19276281
[TBL] [Abstract][Full Text] [Related]
34. Predictive Biomarkers for Endocrine Therapy: Retrospective Study in Tamoxifen and Exemestane Adjuvant Multinational (TEAM) Trial.
Roseweir AK; Bennett L; Dickson A; Cheng K; Quintayo MA; Bayani J; McMillan DC; Horgan PG; van de Velde CJH; Seynaeve C; Hasenburg A; Kieback DG; Markopoulos C; Dirix LY; Rea DW; Mallon EA; Bartlett JMS; Edwards J
J Natl Cancer Inst; 2018 Jun; 110(6):616-627. PubMed ID: 29917140
[TBL] [Abstract][Full Text] [Related]
35. Prognostic role of human epidermal growth factor receptor 2 status in premenopausal early breast cancer treated with adjuvant tamoxifen.
Meattini I; Livi L; Saieva C; Franceschini D; Scotti V; Mangoni M; Loi M; Di Brina L; Zei G; Bonomo P; Greto D; Gelain E; Nori J; Sanchez LJ; Orzalesi L; Bianchi S; Biti G
Clin Breast Cancer; 2013 Aug; 13(4):247-53. PubMed ID: 23684167
[TBL] [Abstract][Full Text] [Related]
36. Two years of adjuvant tamoxifen in premenopausal patients with breast cancer: a randomised, controlled trial with long-term follow-up.
Rydén L; Jönsson PE; Chebil G; Dufmats M; Fernö M; Jirström K; Källström AC; Landberg G; Stål O; Thorstenson S; Nordenskjöld B; ;
Eur J Cancer; 2005 Jan; 41(2):256-64. PubMed ID: 15661551
[TBL] [Abstract][Full Text] [Related]
37. Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response.
Schiff R; Massarweh S; Shou J; Osborne CK
Clin Cancer Res; 2003 Jan; 9(1 Pt 2):447S-54S. PubMed ID: 12538499
[TBL] [Abstract][Full Text] [Related]
38. p27Kip1 is a predictive factor for tamoxifen treatment response but not a prognostic marker in premenopausal breast cancer patients.
Stendahl M; Nilsson S; Wigerup C; Jirström K; Jönsson PE; Stål O; Landberg G
Int J Cancer; 2010 Dec; 127(12):2851-8. PubMed ID: 21351264
[TBL] [Abstract][Full Text] [Related]
39. Cyclin E confers a prognostic value in premenopausal breast cancer patients with tumours exhibiting an infiltrative growth pattern.
Berglund P; Stighall M; Jirström K; Rydén L; Fernö M; Nordenskjöld B; Landberg G
J Clin Pathol; 2008 Feb; 61(2):184-91. PubMed ID: 17483245
[TBL] [Abstract][Full Text] [Related]
40. Progesterone receptor positivity is a predictor of long-term benefit from adjuvant tamoxifen treatment of estrogen receptor positive breast cancer.
Nordenskjöld A; Fohlin H; Fornander T; Löfdahl B; Skoog L; Stål O
Breast Cancer Res Treat; 2016 Nov; 160(2):313-322. PubMed ID: 27722840
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]